Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial

V. Diéras, HS. Han, B. Kaufman, H. Wildiers, M. Friedlander, JP. Ayoub, SL. Puhalla, I. Bondarenko, M. Campone, EH. Jakobsen, M. Jalving, C. Oprean, M. Palácová, YH. Park, Y. Shparyk, E. Yañez, N. Khandelwal, MG. Kundu, M. Dudley, CK. Ratajczak,...

. 2020 ; 21 (10) : 1269-1282. [pub] 20200827

Jazyk angličtina Země Velká Británie

Typ dokumentu klinické zkoušky, fáze III, časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc20027782
E-zdroje Online Plný text

NLK ProQuest Central od 2000-09-01 do Před 2 měsíci
Nursing & Allied Health Database (ProQuest) od 2000-09-01 do Před 2 měsíci
Health & Medicine (ProQuest) od 2000-09-01 do Před 2 měsíci
Public Health Database (ProQuest) od 2000-09-01 do Před 2 měsíci

Odkazy

PubMed 32861273
DOI 10.1016/s1470-2045(20)30447-2
Knihovny.cz E-zdroje

BACKGROUND: BRCA1 or BRCA2-mutated breast cancers are sensitive to poly(ADP-ribose) polymerase (PARP) inhibitors and platinum agents owing to deficiency in homologous recombination repair of DNA damage. In this trial, we compared veliparib versus placebo in combination with carboplatin and paclitaxel, and continued as monotherapy if carboplatin and paclitaxel were discontinued before progression, in patients with HER2-negative advanced breast cancer and a germline BRCA1 or BRCA2 mutation. METHODS: BROCADE3 was a randomised, double-blind, placebo-controlled, phase 3 trial done at 147 hospitals in 36 countries. Eligible patients (aged ≥18 years) had deleterious germline BRCA1 or BRCA2 mutation-associated, histologically or cytologically confirmed advanced HER2-negative breast cancer, an Eastern Cooperative Oncology Group performance status of 0-2, and had received up to two previous lines of chemotherapy for metastatic disease. Patients were randomly assigned (2:1) by interactive response technology by means of permuted blocks within strata (block size of 3 or 6) to carboplatin (area under the concentration curve 6 mg/mL per min intravenously) on day 1 and paclitaxel (80 mg/m2 intravenously) on days 1, 8, and 15 of 21-day cycles combined with either veliparib (120 mg orally twice daily, on days -2 to 5) or matching placebo. If patients discontinued carboplatin and paclitaxel before progression, they could continue veliparib or placebo at an intensified dose (300 mg twice daily continuously, escalating to 400 mg twice daily if tolerated) until disease progression. Patients in the control group could receive open-label veliparib monotherapy after disease progression. Randomisation was stratified by previous platinum use, history of CNS metastases, and oestrogen and progesterone receptor status. The primary endpoint was investigator-assessed progression-free survival per Response Evaluation Criteria in Solid Tumors version 1.1. Efficacy analyses were done by intention to treat, which included all randomly assigned patients with a centrally confirmed BRCA mutation, and safety analyses included all patients who received at least one dose of velilparib or placebo. This study is ongoing and is registered with ClinicalTrials.gov, NCT02163694. FINDINGS: Between July 30, 2014, and Jan 17, 2018, 2202 patients were screened, of whom 513 eligible patients were enrolled and randomly assigned. In the intention-to-treat population (n=509), 337 patients were assigned to receive veliparib plus carboplatin-paclitaxel (veliparib group) and 172 were assigned to receive placebo plus carboplatin-paclitaxel (control group). Median follow-up at data cutoff (April 5, 2019) was 35·7 months (IQR 24·9-43·6) in the veliparib group and 35·5 months (23·1-45·9) in the control group. Median progression-free survival was 14·5 months (95% CI 12·5-17·7) in the veliparib group versus 12·6 months (10·6-14·4) in the control group (hazard ratio 0·71 [95% CI 0·57-0·88], p=0·0016). The most common grade 3 or worse adverse events were neutropenia (272 [81%] of 336 patients in the veliparib group vs 143 [84%] of 171 patients in the control group), anaemia (142 [42%] vs 68 [40%]), and thrombocytopenia (134 [40%] vs 48 [28%]). Serious adverse events occurred in 115 (34%) patients in the veliparib group versus 49 (29%) patients in the control group. There were no study drug-related deaths. INTERPRETATION: The addition of veliparib to a highly active platinum doublet, with continuation as monotherapy if the doublet were discontinued, resulted in significant and durable improvement in progression-free survival in patients with germline BRCA mutation-associated advanced breast cancer. These data indicate the utility of combining platinum and PARP inhibitors in this patient population. FUNDING: AbbVie.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20027782
003      
CZ-PrNML
005      
20210114152342.0
007      
ta
008      
210105s2020 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/S1470-2045(20)30447-2 $2 doi
035    __
$a (PubMed)32861273
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Diéras, Véronique $u Institut Curie, Paris, France; Breast Oncology, Centre Eugène Marquis, Rennes, France. Electronic address: v.dieras@rennes.unicancer.fr.
245    10
$a Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial / $c V. Diéras, HS. Han, B. Kaufman, H. Wildiers, M. Friedlander, JP. Ayoub, SL. Puhalla, I. Bondarenko, M. Campone, EH. Jakobsen, M. Jalving, C. Oprean, M. Palácová, YH. Park, Y. Shparyk, E. Yañez, N. Khandelwal, MG. Kundu, M. Dudley, CK. Ratajczak, D. Maag, BK. Arun,
520    9_
$a BACKGROUND: BRCA1 or BRCA2-mutated breast cancers are sensitive to poly(ADP-ribose) polymerase (PARP) inhibitors and platinum agents owing to deficiency in homologous recombination repair of DNA damage. In this trial, we compared veliparib versus placebo in combination with carboplatin and paclitaxel, and continued as monotherapy if carboplatin and paclitaxel were discontinued before progression, in patients with HER2-negative advanced breast cancer and a germline BRCA1 or BRCA2 mutation. METHODS: BROCADE3 was a randomised, double-blind, placebo-controlled, phase 3 trial done at 147 hospitals in 36 countries. Eligible patients (aged ≥18 years) had deleterious germline BRCA1 or BRCA2 mutation-associated, histologically or cytologically confirmed advanced HER2-negative breast cancer, an Eastern Cooperative Oncology Group performance status of 0-2, and had received up to two previous lines of chemotherapy for metastatic disease. Patients were randomly assigned (2:1) by interactive response technology by means of permuted blocks within strata (block size of 3 or 6) to carboplatin (area under the concentration curve 6 mg/mL per min intravenously) on day 1 and paclitaxel (80 mg/m2 intravenously) on days 1, 8, and 15 of 21-day cycles combined with either veliparib (120 mg orally twice daily, on days -2 to 5) or matching placebo. If patients discontinued carboplatin and paclitaxel before progression, they could continue veliparib or placebo at an intensified dose (300 mg twice daily continuously, escalating to 400 mg twice daily if tolerated) until disease progression. Patients in the control group could receive open-label veliparib monotherapy after disease progression. Randomisation was stratified by previous platinum use, history of CNS metastases, and oestrogen and progesterone receptor status. The primary endpoint was investigator-assessed progression-free survival per Response Evaluation Criteria in Solid Tumors version 1.1. Efficacy analyses were done by intention to treat, which included all randomly assigned patients with a centrally confirmed BRCA mutation, and safety analyses included all patients who received at least one dose of velilparib or placebo. This study is ongoing and is registered with ClinicalTrials.gov, NCT02163694. FINDINGS: Between July 30, 2014, and Jan 17, 2018, 2202 patients were screened, of whom 513 eligible patients were enrolled and randomly assigned. In the intention-to-treat population (n=509), 337 patients were assigned to receive veliparib plus carboplatin-paclitaxel (veliparib group) and 172 were assigned to receive placebo plus carboplatin-paclitaxel (control group). Median follow-up at data cutoff (April 5, 2019) was 35·7 months (IQR 24·9-43·6) in the veliparib group and 35·5 months (23·1-45·9) in the control group. Median progression-free survival was 14·5 months (95% CI 12·5-17·7) in the veliparib group versus 12·6 months (10·6-14·4) in the control group (hazard ratio 0·71 [95% CI 0·57-0·88], p=0·0016). The most common grade 3 or worse adverse events were neutropenia (272 [81%] of 336 patients in the veliparib group vs 143 [84%] of 171 patients in the control group), anaemia (142 [42%] vs 68 [40%]), and thrombocytopenia (134 [40%] vs 48 [28%]). Serious adverse events occurred in 115 (34%) patients in the veliparib group versus 49 (29%) patients in the control group. There were no study drug-related deaths. INTERPRETATION: The addition of veliparib to a highly active platinum doublet, with continuation as monotherapy if the doublet were discontinued, resulted in significant and durable improvement in progression-free survival in patients with germline BRCA mutation-associated advanced breast cancer. These data indicate the utility of combining platinum and PARP inhibitors in this patient population. FUNDING: AbbVie.
650    _2
$a dospělí $7 D000328
650    _2
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
650    _2
$a benzimidazoly $x terapeutické užití $7 D001562
650    _2
$a nádory prsu $x farmakoterapie $x genetika $x patologie $7 D001943
650    _2
$a karboplatina $x terapeutické užití $7 D016190
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a rozvrh dávkování léků $7 D004334
650    _2
$a nežádoucí účinky léčiv $7 D064420
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a geny BRCA1 $7 D019398
650    _2
$a geny BRCA2 $7 D024522
650    _2
$a zárodečné mutace $7 D018095
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a organoplatinové sloučeniny $x terapeutické užití $7 D009944
650    _2
$a paclitaxel $x terapeutické užití $7 D017239
650    _2
$a PARP inhibitory $x terapeutické užití $7 D000067856
650    _2
$a doba přežití bez progrese choroby $7 D000077982
650    _2
$a výsledek terapie $7 D016896
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Han, Hyo S $u Moffitt Cancer Center, Tampa, FL, USA.
700    1_
$a Kaufman, Bella $u Tel-Aviv University, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel.
700    1_
$a Wildiers, Hans $u Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium.
700    1_
$a Friedlander, Michael $u Prince of Wales Clinical School UNSW and Prince of Wales Hospital, Sydney, NSW, Australia.
700    1_
$a Ayoub, Jean-Pierre $u Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.
700    1_
$a Puhalla, Shannon L $u UPMC Cancer Centers, Pittsburgh, PA, USA.
700    1_
$a Bondarenko, Igor $u Dnipropetrovsk Medical Academy, City Clinical Hospital Number 4, Dnipro, Ukraine.
700    1_
$a Campone, Mario $u Institut de Cancérologie de l'Ouest Saint-Herblain, France.
700    1_
$a Jakobsen, Erik H $u Vejle Hospital/Lillebaelt Hospital, Vejle, Denmark.
700    1_
$a Jalving, Mathilde $u University Medical Center Groningen, University of Groningen, Groningen, Netherlands.
700    1_
$a Oprean, Cristina $u University of Medicine and Pharmacy Timisoara and Oncomed SRL, Timisoara, Romania.
700    1_
$a Palácová, Marketa $u Masaryk Memorial Cancer Institute, Brno, Czech Republic.
700    1_
$a Park, Yeon Hee $u Samsung Medical Center, Seoul, South Korea.
700    1_
$a Shparyk, Yaroslav $u Lviv State Regional Treatment and Diagnostic Oncology Center, Lviv, Ukraine.
700    1_
$a Yañez, Eduardo $u Universidad de la Frontera, Temuco, Chile.
700    1_
$a Khandelwal, Nikhil $u AbbVie, North Chicago, IL, USA.
700    1_
$a Kundu, Madan G $u AbbVie, North Chicago, IL, USA.
700    1_
$a Dudley, Matthew $u AbbVie, North Chicago, IL, USA.
700    1_
$a Ratajczak, Christine K $u AbbVie, North Chicago, IL, USA.
700    1_
$a Maag, David $u AbbVie, North Chicago, IL, USA.
700    1_
$a Arun, Banu K $u The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
773    0_
$w MED00011558 $t The Lancet. Oncology $x 1474-5488 $g Roč. 21, č. 10 (2020), s. 1269-1282
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32861273 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20210105 $b ABA008
991    __
$a 20210114152340 $b ABA008
999    __
$a ok $b bmc $g 1608117 $s 1118962
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 21 $c 10 $d 1269-1282 $e 20200827 $i 1474-5488 $m Lancet oncology $n Lancet Oncol. $x MED00011558
LZP    __
$a Pubmed-20210105

Najít záznam

Citační ukazatele

Možnosti archivace